

Medicaid Hepatitis C Subscription Model Update



Medicaid Subscription Model Overview

- Unlimited quantity of hepatitis C treatment at no more than a fixed cost for the state
- Preferred agent is the authorized generic of Epclusa (sofosbuvir/velpatasvir), with no requirement for prior authorization
- Began July 15, 2019

Cost Comparisons

- To gauge performance of the model, we can also look at cost
- Specific rebate amounts are confidential, but we can look at comparisons to alternative strategies
- Comparison 1: Current hepatitis C subscription model (AG Epclusa) versus the next best “subscription” offer from that solicitation (Mavyret)
- Comparison 2: Current hepatitis C subscription model (AG Epclusa) versus the best available offer through our normal preferred drug list development process

Comparison 1

- Current hepatitis C subscription model (AG Epclusa) versus the next best “subscription” offer from that solicitation (Mavyret)
- For year 1, the current hepatitis C subscription model resulted in lower cost by an estimated \$19.1M

Comparison 2

- Current hepatitis C subscription model (AG Epclusa) versus the best available offer through our normal preferred drug list development process
- For year 1, the current hepatitis C subscription model resulted in lower cost by \$29.5M

Summary

- The current subscription model (AG Epclusa) resulted in lower cost relative to the two next best alternatives